{"filings":[{"id":1028284,"accession_number":"0001493152-26-028457","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2026-06-12T20:30:27+00:00","items":["5.03","9.01"],"status":"ready","headline":"GT Biopharma reduces stockholder meeting quorum from majority to one-third","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amendment to bylaws effective June 8, 2026.","Quorum lowered from majority to not less than one-third of outstanding voting shares.","Change aims to improve meeting attendance amid broker non-voting trends.","Company is fully remote as of July 1, 2024; no principal executive office."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":591680,"accession_number":"0001493152-26-024913","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2026-05-22T12:00:37+00:00","items":["3.01","9.01"],"status":"ready","headline":"GT Biopharma receives Nasdaq extension to Nov 16, 2026 to meet $1 minimum bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Staff letter on May 20, 2026 granting 180-day extension until Nov 16, 2026 for minimum bid price compliance.","Previously received initial deficiency notice on Nov 20, 2025; initial 180-day period expired May 19, 2026.","Company meets all other Nasdaq Capital Market initial listing requirements except for minimum bid price.","No assurance of compliance; company will monitor bid price and assess options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91273,"accession_number":"0001493152-26-015413","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GT Biopharma enters agreement with Univ. of Minnesota for Phase 1a/1b trial of GTB-5550","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement for IND 169118 GTB-5550 (camB7-H3 TriKE) in advanced solid tumors that failed prior therapy.","University of Minnesota will sponsor as investigator-initiated Phase 1a/1b trial.","Budget of up to $3.8 million over three years, funded by GT Biopharma.","Agreement effective April 3, 2026; 30-day termination clause for either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101259,"accession_number":"0001493152-26-008442","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["4.02","9.01"],"status":"ready","headline":"GT Biopharma restates Q2/Q3 2025 financials; Greenshoe Rights liability misclassified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee concluded non-reliance on Q2 and Q3 2025 Form 10-Q after finding Greenshoe Rights should have been liability under ASC 480.","Restatement adds $28.7M liability and loss on initial recognition in Q2; net loss restated to $30.2M from $1.4M.","For Q3, change in fair value of Greenshoe Rights added $11.4M income; net loss restated to $22.6M from $5.3M.","Greenshoe Rights liability extinguished and reclassified to equity in September 2025 after redemption rights waiver.","Company plans to file amended 10-Qs for affected periods and includes restated data in 2025 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117614,"accession_number":"0001493152-25-025162","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"GT Biopharma receives Nasdaq delisting notice for low bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified GT Biopharma on Nov 20, 2025 that stock closed below $1 for 30 consecutive days, violating Minimum Bid Price Requirement.","Company has 180 calendar days until May 19, 2026 to regain compliance by closing at $1 for at least 10 consecutive business days.","If not cured, may qualify for additional 180-day period if it meets other listing standards and notifies Nasdaq of intent to reverse split.","Company says it will monitor bid price and assess options; no assurance compliance will be regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117613,"accession_number":"0001493152-25-022631","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GT Biopharma reports Q3 2025 net loss of $3.1M; cash $2.6M funds into Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.1M for Q3 2025 improved from $3.4M in Q3 2024.","Cash and equivalents $2.6M expected to fund operations into Q1 2026.","R&D expenses fell to $0.6M from $1.3M due to lower production and material costs.","Phase 1 GTB-3650 trial now in Cohort 4 at 10 µg/kg/day; next update Q1 2026.","GTB-5550 IND submission for B7H3 tumors expected late Dec 2025 or Jan 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134046,"accession_number":"0001493152-25-015725","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"GT Biopharma Series L Preferred holders waive redemption rights – all holders now in agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All Series L 10% Convertible Preferred Stock holders have waived redemption rights under Section 10 of the Certificate of Designations.","Additional holder provided waiver on September 25, 2025, completing the agreement across all holders.","Waiver eliminates potential redemption trigger that could require cash outlay, improving liquidity.","No financial impact disclosed; modification alters preferred stockholder rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134045,"accession_number":"0001493152-25-014684","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"GT Biopharma series L preferred holders waive redemption rights permanently","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Holders of Series L 10% Convertible Preferred Stock waived redemption rights under Section 10 of the Certificate of Designations.","Waivers were provided on September 17, 18, and 23, 2025, and are permanent.","Waiver does not affect other rights of the preferred stockholders under the Certificate of Designations.","The company requested the waiver; certain holders countersigned the form of waiver."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134044,"accession_number":"0001493152-25-012479","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GT Biopharma renews CEO Michael Breen for two-year term, effective April 29, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Michael Breen's employment renewed for two years from April 29, 2025, with automatic two-year renewals unless 90-day notice given.","Breen continues as Executive Chairman and CEO; may perform duties from UK or elsewhere outside US.","Amendment No. 3 signed August 26, 2025, retroactively effective April 29, 2025.","No other changes to Breen's compensation or benefits under the existing employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134043,"accession_number":"0001641172-25-020847","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GT Biopharma stockholders approve share issuance for May 2025 financings and omnibus plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four director nominees (Breen, Casamento, Kramer, Mun-Gavin) elected with 1.18M+ votes each, no votes under 14K.","Ratification of Weinberg & Company as FY 2025 auditor passed: 1.79M for, 59K against.","Non-binding advisory vote on executive compensation approved: 1.17M for, 20K against.","Approved issuance of up to 19.99% of outstanding common stock related to May 2025 purchase agreements and convertible preferred.","Amendment No. 1 to 2022 Omnibus Incentive Plan, increasing shares by 583,334, approved: 1.15M for, 35K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150799,"accession_number":"0001641172-25-014700","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"GT Biopharma appoints new director, amends equity facility to raise up to $20M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Andrew Ritter resigned from board effective June 9, 2025.","David C. Mun-Gavin appointed as director and chair of compensation committee on June 10, 2025.","Amendment to Common Shares Purchase Agreement increases Bristol Capital's beneficial ownership limit to 9.99%.","Equity facility remains at $20M; change gives more flexibility for future stock sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150798,"accession_number":"0001641172-25-012481","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"GT Biopharma expands private placement to $5.95M, adds new investor Marzilli","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased Series L preferred offering to 6,612 shares ($5.95M) from 6,056 shares ($5.45M) via First Amendment on May 21, 2025.","Added Robert A. Marzilli as new purchaser; Majority Purchasers (Five Narrow Lane, Bristol Capital) consented.","Filed Certificate of Increase raising authorized Series L shares from 28,056 to 30,630.","Greenshoe right: Purchasers may buy up to $24.0M additional preferred stock on same terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150797,"accession_number":"0001641172-25-009941","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GT Biopharma appoints two new directors; two resign; board reduced to four","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 4 to 6 on May 7; Hilary Kramer appointed as non-employee director.","Bruce Wendel resigned from Board and all committees on May 7.","Andrew Ritter appointed as non-employee director on May 8.","Rajesh Shrotriya resigned from Board and all committees on May 12.","Board reduced to 4 members; Kramer chairs Nominating Committee, Ritter chairs Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150796,"accession_number":"0001641172-25-009854","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"GT Biopharma raises $5.45M via convertible preferred stock and warrants with greenshoe option up to $19.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of up to 6,056 shares of Series L 10% Convertible Preferred Stock at $1,000 stated value; net proceeds $5.45M.","Conversion price $2.043 per share; warrants exercisable at same price for five years; full ratchet anti-dilution with floor of $0.454.","Dividends at 10% annual rate until May 2026, increasing to 12% thereafter; payable quarterly in cash or common stock.","Company to seek shareholder approval for issuance over 19.99% of outstanding common stock; officers/directors locked up.","Registration rights agreement requires filing within 30 days; liquidated damages of 1.5% per month if not effective within 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150795,"accession_number":"0001641172-25-008682","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GT Biopharma appoints Michael Breen as CEO, effective April 29, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Breen appointed CEO for a two-year term; he had served as Interim CEO since March 2022.","Breen continues as Executive Chairman and Board member, roles held since January and November 2021.","Breen is a UK-qualified solicitor and former senior partner at Clyde & Co., advising biotech clients.","No compensatory terms or changes to existing arrangements disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150794,"accession_number":"0001641172-25-002750","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"GT Biopharma issues pre-funded warrant to Cytovance for 326,251 shares as service consideration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued pre-funded warrant to purchase up to 326,251 shares of common stock at $0.0001 per share.","Aggregate exercise price of $846,562.50 was pre-funded via services rendered by Cytovance Biologics.","Warrant is immediately exercisable with a beneficial ownership limitation; no cash received.","Issued without registration under Section 4(a)(2) of Securities Act as a private transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169738,"accession_number":"0001493152-25-008387","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"GT Biopharma induces exercise of 302K warrants at $2.27, raises ~$0.7M; issues new warrants for 604K shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered inducement letters with holders of 302,069 existing warrants to exercise at reduced price of $2.27/share, raising ~$0.7M gross proceeds.","In exchange, issued Series A (5-year term) and Series B (18-month term) inducement warrants at $2.02 exercise price for up to 604,138 shares total.","New warrants are unregistered; company to file resale registration statement within 30 days.","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169737,"accession_number":"0001493152-25-003707","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GT Biopharma doses first patient in Phase 1 trial of GTB-3650 for hematologic malignancies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GTB-3650 is a second-generation TriKE using camelid nanobody technology to improve potency and binding affinity.","Phase 1 dose-escalation trial will enroll up to ~14 patients (7 cohorts) with r/r CD33+ AML and MDS.","Initial clinical data from the study expected in 2025.","Trial assesses safety, PK, PD, NK cell expansion, and clinical activity over up to 4 months of treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186783,"accession_number":"0001493152-24-047994","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"GT Biopharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter on Nov 21, 2024: stockholders' equity fell below $2.5M required for continued listing.","Company does not meet market value of listed securities or net income alternatives.","Must submit compliance plan by Jan 6, 2025; Nasdaq may grant up to 180-day extension.","If plan not accepted, Company may appeal to Nasdaq Hearings Panel.","Stock continues trading under GTBP; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186782,"accession_number":"0001493152-24-047085","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GT Biopharma enters Phase 1 clinical trial agreement with U of Minnesota for GTB-3650 in MDS/AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement for investigator-initiated Phase 1 trial of GTB-3650 (CD16/IL-15/CD33 TriKE) in high-risk MDS, relapsed/refractory AML, MRD.","Budget up to ~$2 million over three years, funded entirely by GT Biopharma.","University of Minnesota sponsors the IND and acts as sponsor-investigator; Company supplies study drug and funding.","Study data owned by University; Company may use data subject to consent and laws; each party may publish results.","Agreement terminable on 30 days' notice by either party, or immediately for safety reasons."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203331,"accession_number":"0001493152-24-036381","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GT Biopharma repositions Dr. Miller as Consulting Senior Medical Director for conflict-of-interest compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jeffrey Miller ceased as Consulting Chief Medical Officer and Consulting Chief Scientific Officer effective September 16, 2024.","He commenced as Consulting Senior Medical Director to align with University of Minnesota conflict-of-interest policies.","The change precedes the Phase I clinical trial of GTB-3650 compound at the University of Minnesota."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219697,"accession_number":"0001493152-24-025382","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GT Biopharma receives FDA clearance for IND of GTB-3650; Phase 1 trial to start H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA cleared IND for GTB-3650, an NK cell engager for CD33+ leukemias; Phase 1 trial initiation expected H2 2024.","Initial Phase 1 clinical data for GTB-3650 expected in H1 2025.","GTB-5550 IND submission (B7H3 solid tumors) expected Q1 2025; basket trial in six solid tumor types planned for 2025.","Company becomes fully remote effective July 1, 2024; stockholder communications to San Francisco address.","Cash runway expected to fund operations into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219696,"accession_number":"0001493152-24-025269","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GT Biopharma annual meeting elects all four directors, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum: 691,084 shares (50.05%) represented at June 25 annual meeting.","All four directors elected: Breen (298,002 for), Shrotriya (295,782), Wendel (229,004), Casamento (266,456).","Ratification of Weinberg & Company as auditor: 579,726 for, 89,595 against, 21,763 abstain.","Non-binding advisory vote on executive compensation approved: 277,591 for, 47,062 against, 6,392 abstain, 360,039 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219695,"accession_number":"0001493152-24-023195","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GT Biopharma appoints Alan Urban as CFO after terminating Manu Ohri","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Manu Ohri's employment as CFO terminated effective June 3, 2024.","Alan L. Urban appointed CFO; previously CFO at SRAX, Creek Road Miners, Research Solutions.","Urban receives $375,000 base salary, up to 40% bonus, and equity award eligibility after 3 months.","Employment agreement for one-year initial term with automatic renewal and severance terms.","Urban reports to Executive Chairman & Interim CEO Michael Breen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219694,"accession_number":"0001493152-24-021078","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"GT Biopharma raises $3.2M in registered direct offering; issues warrants at $4.35 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.2M from sale of 740,000 shares at $4.35/share in registered direct offering.","Concurrent private placement of 740,000 warrants exercisable at $4.35, five-year term.","Closing expected on or about May 23, 2024, subject to customary conditions.","Roth Capital Partners acted as exclusive placement agent; fees and expenses will be deducted.","Net proceeds to be used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219693,"accession_number":"0001493152-24-017209","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GT Biopharma amends agreement with Cytovance to raise ownership cap from 4.9% to 9.9%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cytovance's beneficial ownership limit raised from 4.9% to 9.9% of GT Biopharma's outstanding common stock.","Amendment effective April 25, 2024; all other terms of the Aug 24, 2022 Settlement and Investment Agreement unchanged.","Excess shares above 9.9% cap to be issued in quarterly installments with 10-day prior notice from GTBP.","Executed by GTBP Executive Chairman Michael Breen and Cytovance CFO David Knauss."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239484,"accession_number":"0001493152-24-004587","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"GT Biopharma announces 1-for-30 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1:30 effective 5:00 PM ET Feb 2, 2024; post-split trading begins Feb 5.","Outstanding shares reduced from ~41.4M to ~1.38M; authorized shares unchanged at 250M.","No fractional shares issued; stockholders receive cash for fractional shares.","Proportionate adjustments to outstanding stock options and equity awards.","Action intended to regain Nasdaq $1.00 minimum bid price; ticker remains GTBP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257012,"accession_number":"0001493152-23-045714","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GT Biopharma shareholders approve reverse stock split authorization at ratio of 1:5 to 1:30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Dec 18, 2023; 58.13% of outstanding shares voted.","Proposal passed with 20.3M for, 3.8M against, 17k abstain.","Board has discretion to set final ratio within 1-for-5 to 1-for-30 range.","Reverse split authorization is part of charter amendment to be announced publicly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257011,"accession_number":"0001493152-23-043582","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GT Biopharma submits IND to FDA for GTB-3650 for CD33+ leukemia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IND submitted for GTB-3650, a 2nd generation nanobody TriKE targeting CD33+ leukemia (relapsed/refractory AML and high-risk MDS).","Interim CEO Michael Breen says company aims to move GTB-3650 into the clinic expeditiously in 2024.","GTB-3650 is based on the proprietary TriKE NK cell engager platform licensed from University of Minnesota."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274351,"accession_number":"0001493152-23-029841","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"GT Biopharma gets Nasdaq extension to Feb 20, 2024 for bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company has until Feb 20, 2024 to close at $1.00 for 10 consecutive days to regain compliance.","May consider a reverse stock split to meet the Minimum Bid Price Requirement.","No immediate effect on listing; common stock continues trading on Nasdaq Capital Market under GTBP.","No assurance that compliance will be regained; company will monitor bid price and consider options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274350,"accession_number":"0001493152-23-023367","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GT Biopharma annual meeting elects four directors, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Michael Breen, Rajesh Shrotriya, Bruce Wendel, and Charles Casamento with majority for votes.","Ratified Weinberg & Company as independent auditor for 2023: 19,823,634 for, 849,463 against.","Advisory say-on-pay passed: 8,916,400 for, 2,034,860 against, 13,805 abstain, 9,736,535 broker non-votes.","Quorum of 55.2% represented at meeting (20,701,600 of 37,493,065 shares outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291592,"accession_number":"0001493152-23-015385","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GT Biopharma appoints Charles Casamento to board; Alan Urban resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles J. Casamento appointed to board effective May 1, 2023, to fill vacant seat.","Casamento to serve on Audit, Compensation, and Nominating & Governance committees.","Alan Urban resigned from board on May 1, 2023, to pursue new career opportunities.","Casamento has >35 years biopharma experience, formerly CEO of Questcor Pharmaceuticals and Osteologix.","Casamento currently serves on boards of four NASDAQ-listed biotechs: Eton, First Wave, PaxMedica, Relmada."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312366,"accession_number":"0001493152-23-006284","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"GT Biopharma receives Nasdaq deficiency notice for bid price below $1.00 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Feb 22, 2023; stock closed below $1.00 for 30 consecutive business days.","Has 180 calendar days, until August 21, 2023, to regain compliance by closing at $1.00+ for 10 consecutive business days.","May qualify for a second 180-day period if it meets other listing standards and provides written notice.","Company intends to monitor bid price and consider available options to cure the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312365,"accession_number":"0001493152-23-000198","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"GT Biopharma raises $6.5M in registered direct offering of shares and warrants at $1.00 per unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6.5M shares or pre-funded warrants plus 6.5M warrants to purchase common stock.","Gross proceeds of $6.5 million, before placement agent fees and expenses.","Warrants exercisable at $1.00 per share, beginning six months after issuance, for five years.","H.C. Wainwright & Co. acted as exclusive placement agent; cash fee of $390,000 paid.","Net proceeds to be used for general corporate purposes; closing expected January 4, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330920,"accession_number":"0001493152-22-035311","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GT Biopharma announces departure of President of R&D and CMO Gregory Berk","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gregory Berk no longer employed as President of R&D and Chief Medical Officer effective December 8, 2022.","No successor or interim replacement named in the filing.","Departure comes as GT Biopharma (GTBP) advances its cancer immunotherapy pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330919,"accession_number":"0001493152-22-031139","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"GT Biopharma adopts amended bylaws with proxy access and exclusive forum provisions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended bylaws effective Nov 3, 2022 include proxy access for eligible long-term shareholders.","Updated advance notice requirements for director nominations and shareholder proposals.","Added exclusive forum provision for certain legal actions.","Clarified authority to adjourn shareholder meetings when quorum not present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330918,"accession_number":"0001493152-22-028260","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2022-10-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GT Biopharma shareholders vote to reduce authorized common stock from 750M to 250M shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting held Oct 10, 2022; 17,442,945 of 31,092,498 shares represented (56.1%).","Proposal to ratify amendment reducing authorized common stock from 750M to 250M shares passed.","Vote: 17,201,108 For, 227,621 Against, 14,216 Abstain.","The amendment was previously proposed at the 2022 Annual Meeting as Proposal No. 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330917,"accession_number":"0001493152-22-027568","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2022-10-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GT Biopharma adjourns special shareholders meeting due to lack of quorum; reconvened Oct 10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Sept 28 lacked quorum; adjourned to Oct 10, 2022 at 11 a.m. PST.","Record date remains Aug 8, 2022; prior votes count unless changed.","Proposal unchanged: ratify discretionary broker voting on authorized share reduction from 750M to 250M.","Company urges all shareholders to vote by Oct 9 to ensure quorum at reconvened meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348459,"accession_number":"0001493152-22-024422","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2022-08-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"GT Biopharma settles $6.5M Cytovance debt with stock and cash; aims for IND filings by Mar/Jun 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,222,281 shares to Cytovance to settle $3.25M of invoices; will pay another $3.25M in cash over three months.","Future invoices paid 50% cash and 50% in common stock at closing price; materials invoices all cash.","Cytovance to facilitate GTB-3650 IND by March 31, 2023 and GTB-5550 IND by June 30, 2023, subject to conditions.","Cytovance ownership capped at 4.9% of outstanding; daily resale limited to 50k shares or 1/3 of avg weekly volume.","Parties release each other from claims arising prior to agreement effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348458,"accession_number":"0001493152-22-023342","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K/A","filed_at":"2022-08-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GT Biopharma amends 8-K to correct vote tabulation on authorized shares reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 4 to reduce authorized shares from 750M to 250M passed with 19,568,632 For, 215,253 Against, 141,506 Abstain.","Original filing incorrectly classified Proposal 4 as non-routine; it was routine, allowing broker discretionary votes.","Company plans special stockholder meeting to ratify inclusion of discretionary broker votes in Proposal 4 tabulation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365153,"accession_number":"0001493152-22-016671","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GT Biopharma shareholders approve all proposals including authorized share reduction and 2022 Omnibus Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Breen, Shrotriya, and Wendel with majority support (for votes 58-61% of shares present).","Ratified Weinberg & Company as independent auditor for FY2022 (19.7M for, 0.2M against).","Approved 2022 Omnibus Incentive Plan authorizing up to 5M shares of common stock.","Approved amendment to reduce authorized common stock from 750M to 250M shares (19.6M for).","Advisory say-on-pay passed (63.7% of votes cast) and frequency set at 1 year (11.9M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365152,"accession_number":"0001493152-22-016394","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GT Biopharma appoints Alan L. Urban to Board and Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan L. Urban appointed to fill vacant Board seat and serve on Audit Committee effective June 9, 2022.","Board determined Urban qualifies as independent director under Nasdaq rules.","Urban has 25+ years finance/accounting experience, including CFO at Research Solutions (RSSS) and ReachLocal (RLOC).","Urban is a CPA (inactive) since 1998; holds B.S. in Accounting from California State University, Northridge."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384752,"accession_number":"0001493152-22-006294","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GT Biopharma names Michael Breen Interim CEO; Gregory Berk becomes President R&D/CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Breen named Interim CEO effective March 2, 2022; base compensation raised to $515,000.","Gregory Berk ceases role as Interim CEO but remains President of R&D and CMO; base salary increased to $437,750.","Both appointments effective March 2, 2022; no other officer changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384751,"accession_number":"0001654954-22-001828","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2022-02-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GT Biopharma appoints Manu Ohri as CFO, replacing Gavin Choy as Acting CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Manu Ohri appointed CFO effective Feb 14, 2022; Gavin Choy ceases as Acting CFO.","Annual base salary of $325,000; target bonus up to 40% of base salary.","Stock award of 25,000 shares and option to purchase 175,000 shares vesting over 3 years.","Options fully accelerate upon a change of control; employment agreement to be signed.","Ohri is a CPA with prior CFO experience at ToughBuilt Industries and Big 4 background."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402631,"accession_number":"0001654954-21-013517","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2021-12-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GT Biopharma regains Nasdaq compliance for independent director and audit committee rules","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Staff letter on Dec 22, 2021 confirming compliance with Listing Rule 5605(b)(1).","Prior non-compliance stemmed from Michael Breen's appointment as Executive Chairman on Nov 8, 2021.","Nasdaq had notified the company of the deficiency on Nov 23, 2021.","Compliance restored following resignation of director Anthony Cataldo effective Dec 15, 2021; matter closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402630,"accession_number":"0001654954-21-013424","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2021-12-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GT Biopharma director Anthony Cataldo resigns from board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Cataldo resigned as a member of the Board of Directors on December 15, 2021.","Filing provides no reason for resignation or any details about a successor.","The resignation reduces the board size; no immediate replacement announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402629,"accession_number":"0001654954-21-012629","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2021-11-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"GT Biopharma fails Nasdaq independent director rule; cure until Nov 2022","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Nov 23, 2021 for non-compliance with Listing Rule 5605 after appointing Michael Breen as Executive Chairman.","Breen resigned from Audit, Compensation, and Nominating Committees on Nov 23, 2021, triggering the deficiency.","Cure period runs until earlier of next annual shareholders' meeting or Nov 8, 2022 (or May 9, 2022 if meeting before).","Company is reviewing independent director candidates and expects to regain compliance within the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402628,"accession_number":"0001654954-21-011550","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2021-11-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GT Biopharma files 8-K to announce updated corporate presentation on website; no specifics disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing states corporate presentation as of Nov 1, 2021 was posted to company website.","Presentation filed as Exhibit 99.1 but full content not provided in filing text.","No financial results, guidance, or operational changes mentioned in the filing.","Ticker: GTBP; common stock listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421548,"accession_number":"0001654954-21-010321","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2021-09-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GT Biopharma files 8-K regarding ESMO 2021 presentation; no financial results disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Dr. Jeffrey Miller presented on GT Biopharma's drug candidates at ESMO Congress 2021.","Updated corporate presentation posted to website as of Sept 20, 2021.","No specific clinical data or financial figures included in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421547,"accession_number":"0001654954-21-009965","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2021-09-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GT Biopharma holds business teleconference on Sep 13, 2021; presentation slide content not disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company presented business overview via teleconference on September 13, 2021.","Presentation filed as Exhibit 99.1 but no substantive financial or operational details were included in the 8-K.","No earnings, guidance, or material events disclosed in the filing.","The event appears to be a routine investor update; no specific facts available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14255664.571683673,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-13T23:59:59+00:00|421547"}